Breaking News Instant updates and real-time market news.

INFN

Infinera

$6.90

0.07 (1.02%)

, APPS

Digital Turbine

$2.02

-0.04 (-1.94%)

17:27
02/07/18
02/07
17:27
02/07/18
17:27

On The Fly: After Hours Movers

UP AFTER EARNINGS: Infinera (INFN), up 18.6%... Digital Turbine (APPS), up 11.4%... Synaptics (SYNA), up 6.5%... CSRA (CSRA), up 2.9%... Fiserv (FISV), up 2.5%... Prudential Financial (PRU), up 1.6%. ALSO HIGHER: Gain Capital (GCAP), up 7.5% after it reported that January retail active accounts rose 6.3% year-over-year... athenahealth (ATHN), up 0.9% after it named former GE (GE) CEO Jeff Immelt as chairman of its board of directors. DOWN AFTER EARNINGS: iRobot (IRBT), down 20.5%... Lannett (LCI), down 12.3%... Inphi (IPHI), down 10.8%... TTM Technologies (TTMI), down 9.2%... Yelp (YELP), down 4.9%... Take-Two (TTWO), down 3.5%... O'Reilly Automotive (ORLY), down 1.2%. ALSO LOWER: Everspin Technologies (MRAM), down 12.4% after it filed to sell common stock and after it provided preliminary Q4 revenue... MediciNova (MNOV), down 4.8% after it announced a common stock offering... Eversource Energy (ES), down 3.3% after it raised its quarterly dividend 6.3%.

INFN

Infinera

$6.90

0.07 (1.02%)

APPS

Digital Turbine

$2.02

-0.04 (-1.94%)

SYNA

Synaptics

$41.00

0.05 (0.12%)

CSRA

CSRA

$31.35

0.8 (2.62%)

FISV

Fiserv

$129.17

-1.58 (-1.21%)

PRU

Prudential

$111.17

0.18 (0.16%)

GCAP

GAIN Capital

$6.53

-0.2 (-2.97%)

ATHN

athenahealth

$134.08

1.32 (0.99%)

GE

General Electric

$15.25

-0.02 (-0.13%)

IRBT

iRobot

$88.04

0.95 (1.09%)

LCI

Lannett

$20.40

0.6 (3.03%)

IPHI

Inphi

$29.71

-2.38 (-7.42%)

TTMI

TTM Technologies

$15.48

-0.08 (-0.51%)

YELP

Yelp

$44.94

0.66 (1.49%)

TTWO

Take-Two

$117.19

-1.08 (-0.91%)

ORLY

O'Reilly Automotive

$252.08

-2.82 (-1.11%)

MRAM

Everspin Technologies

$8.68

0.15 (1.76%)

MNOV

MediciNova

$9.73

-1.02 (-9.49%)

ES

Eversource

$56.89

-0.65 (-1.13%)

  • 07

    Feb

  • 07

    Feb

  • 07

    Feb

  • 07

    Feb

  • 07

    Feb

  • 07

    Feb

  • 07

    Feb

  • 07

    Feb

  • 07

    Feb

  • 07

    Feb

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 12

    Feb

  • 13

    Feb

  • 13

    Feb

  • 14

    Feb

  • 14

    Feb

  • 20

    Feb

  • 21

    Feb

  • 26

    Feb

  • 06

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 16

    Mar

  • 29

    Mar

  • 21

    Jul

  • 08

    Feb

  • 08

    Feb

INFN Infinera
$6.90

0.07 (1.02%)

11/06/17
GSCO
11/06/17
DOWNGRADE
Target $22
GSCO
Neutral
Finisar downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Doug Clark downgraded Finisar (FNSR) to Neutral and his Telecom Equipment coverage view to Neutral from Attractive citing a more cautious stance on the optical component cycle. The analyst sees softening end markets, rising inventories and industry capacity. For Finisar, which reports earnings in early December, Clark thinks the company's guidance has "significant downside risk" relative to consensus expectations. The analyst cut his price target for the shares to $22 from $27. Finisar closed the trading day down 15c to $19.25. Elsewhere in Telecom Equipment sector, Clark has Buy ratings on Arris (ARRS) and Infinera (INFN), Neutral ratings on Acacia Communications (ACIA), Ciena (CIEN) and Lumentum (LITE), and a Sell rating on Adtran (ADTN).
11/09/17
MKMP
11/09/17
DOWNGRADE
MKMP
Neutral
Infinera downgraded to Neutral from Buy at MKM Partners
11/09/17
MKMP
11/09/17
DOWNGRADE
Target $9.5
MKMP
Neutral
Infinera cut to Neutral at MKM Partners on negative customer consolidation
As reported earlier, MKM Partners analyst Michael Genovese downgraded Infinera to Neutral from Buy and lowered his price target to $9.50 from $13. Genovese says his June rating upgrade was based on expectations of revenue growth and margin expansion from an upgrade in technology platform and several product launches, but since then, the company has posted two consecutive quarters of disappointing outlook. The analyst notes that some of the drivers of lower outlook was from a weaker overall market growth and greater than expected negative impact from customer consolidation and tighter competition.
11/09/17
CHLM
11/09/17
NO CHANGE
Target $10
CHLM
Buy
Infinera price target lowered to $10 from $15 at Craig-Hallum
Craig-Hallum analyst Christian Schwab lowered his price target for Infinera to $10 from $15 following quarterly results as challenging market conditions persist. The analyst reiterates a Buy rating on the shares.
APPS Digital Turbine
$2.02

-0.04 (-1.94%)

04/25/17
CHLM
04/25/17
UPGRADE
Target $1.5
CHLM
Buy
Digital Turbine upgraded to Buy from Hold at Craig-Hallum
Craig-Hallum analyst Mike Malouf upgraded Digital Turbine to Buy and raised his price target for the shares to $1.50 from $1.10. The company now has its Ignite platform installed on virtually every new Android phone for both AT&T and Verizon, Malouf tells investors in a research note. He expects the June quarter to be Digital's first ever positive operating cash flow quarter.
03/30/17
03/30/17
UPGRADE
Target $1.3

Buy
Digital Turbine upgraded to Buy at Roth Capital
As previously reported, Roth Capital analyst Brian Alger upgraded Digital Turbine (APPS) to Buy from Neutral saying numerous signs indicate that the fundamental risk to its story has been "dramatically reduced." The analyst notes that meetings at Mobile World Congress as well as his annual conference lead him to believe the strategic positioning remains as strong, if not stronger, than ever. With the March quarter effectively complete, and the launch of Samsung's (SSNLF) Galaxy S8 now confirmed for April 21st, Alger sees "substantially more" upside potential than risk. He also raised his price target on Digital Turbine's shares to $1.30 from $1.10.
03/30/17
ROTH
03/30/17
UPGRADE
ROTH
Buy
Digital Turbine upgraded to Buy from Neutral at Roth Capital
SYNA Synaptics
$41.00

0.05 (0.12%)

12/08/17
OPCO
12/08/17
UPGRADE
OPCO
Perform
Oppenheimer says negatives priced in, upgrades Synaptics to Perform
Oppenheimer analyst Andrew Uerkwitz upgraded Synaptics to Perform from Underperform saying near-term downside is limited. Negative catalysts like share loss at Samsung and Apple are well understood and mostly priced in, Uerkwitz tells investors in a research note. The analyst, however, maintains a fundamental negative view of the company's market position and mobile opportunities.
12/08/17
OTRG
12/08/17
NO CHANGE
OTRG
Synaptics likely lost Samsung S9 fingerprint sensor, says OTR Global
OTR Global's checks indicate Synaptics (SYNA) has lost the fingerprint sensor in Samsung's upcoming Galaxy S9 smartphone.
02/05/18
KEYB
02/05/18
NO CHANGE
Target $60
KEYB
Overweight
Apple iPhone X challenges create opportunities for Synaptics, says KeyBanc
KeyBanc analyst John Vinh says that while read-throughs indicate worse than expected China smartphone trends could put guidance at risk, we believe this is already reflected in Synaptics (SYNA) lowered expectations. Additionally, the analyst believes the recent challenges related to disappointing Apple (AAPL) iPhone X sell-through highlight a positive opportunity for COF DDIC, as it extends the tail for LCD at Apple/industry, and carries a higher ASP. Vinh remains confident of Synaptics' longer-term story, including in-display fingerprint, and smarthome/Internet of Things. He reiterates an Overweight rating and $60 price target on Synaptics' shares.
01/12/18
KEYB
01/12/18
UPGRADE
Target $60
KEYB
Overweight
Synaptics upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst John Vinh upgraded Synaptics to Overweight with a $60 price target. Meetings at this year's Consumer Electronics Show with supply partners and competitors left the analyst "incrementally more positive" regarding Synaptics' opportunity associated with in-display fingerprint. Vinh also gained a greater appreciation for the company's smart home opportunity, at both Amazon (AMZN) and Google (GOOG) as well as with Asia operators. He now has greater confidence in Synaptics' turnaround story.
CSRA CSRA
$31.35

0.8 (2.62%)

12/27/17
LOOP
12/27/17
NO CHANGE
LOOP
Loop says Federal IT services companies to see strong benefit from tax changes
Loop Capital analyst Joseph Vafi noted that federal IT services companies should see an outsized benefit from changes to the corporate tax code, stating that a reduction in the federal corporate tax rate may be offset a bit for some in the space due to the disallowance of deductibility of interest expense. He points to CACI (CACI), CSRA (CSRA), ManTech (MANT), NIC Inc. (EGOV), ICF International (ICFI) and Green Dot (GDOT) as among those who stand to benefit from the new tax law.
10/05/17
JEFF
10/05/17
DOWNGRADE
Target $35
JEFF
Hold
CSRA assumed with a Hold from Buy at Jefferies
Jefferies analyst Sheila Kahyaoglu downgraded CSRA (CSRA) to Hold and lowered her price target for the shares to $35 from $37 after assuming coverage of the name. The company's transition of mature programs into new contracts will likely result in margin contraction, Kahyaoglu tells investors in a research note. The analyst this morning also upgraded Leidos (LDOS) to Buy.
11/21/17
STFL
11/21/17
INITIATION
Target $39
STFL
Buy
CSRA resumed with a Buy at Stifel
Stifel analyst Joseph DeNardi resumed coverage of CSRA with a Buy rating and $39 price target.
10/25/17
WELS
10/25/17
NO CHANGE
WELS
Wells Fargo upgrades three to Outperform in Government Services
Wells Fargo analyst Ed Caso upgraded CACI (CACI), Leidos (LDOS) and SAIC (SAIC) to Outperform from Market Perform while reiterating Outperform ratings on Booz Allen (BAH) and favorite idea CSRA (CSRA). The analyst sees an improving fundamental backdrop for funding levels and pricing amid a "rising global threat environment." Further, he believes the expected resolution in December of the 2018 federal government appropriations should drive national security funding above the current caps set under the Budget Control Act of 2011, while doing "limited damage" to civilian agency budgets. The sector can also benefit meaningfully from any reduction in the U.S. corporate tax rate, Caso tells investors in a research note. He raised his price target for CACI to $158 from $132, for Leidos to $69 from $58 and for SAIC to $80 from $70.
FISV Fiserv
$129.17

-1.58 (-1.21%)

12/21/17
OPCO
12/21/17
NO CHANGE
OPCO
Black Knight, Fiserv among beneficiaries of tax reform, says Oppenheimer
Oppenheimer analyst Glenn Greene anticipates Black Knight (BKI), Fiserv (FISV), Jack Henry (JKHY), SEI Investments (SEIC) and TSYS (TSS) could see the largest relative benefits given high percentage of domestic earnings, with 20%-plus estimated earnings accretion. Alternatively, the analyst believes Cognizant (CTSH), First Data (FDC) and Infosys (INFY) could see more modest benefit, considering Cognizant/Infosys' lower proportion of domestic earnings and First Data's elevated level of debt/interest expense. PayPal (PYPL) is not expected to benefit from tax reform, and could actually see a modest increase in its effective tax rate, he adds.
01/17/18
FBCO
01/17/18
NO CHANGE
Target $140
FBCO
Neutral
Fiserv price target raised to $140 from $126 at Credit Suisse
Credit Suisse analyst Paul Condra raised his price target for Fiserv to $140 from $126, citing stability and tax benefit. The analyst reiterates a Neutral rating on the shares.
01/24/18
BARD
01/24/18
NO CHANGE
Target $160
BARD
Outperform
Fiserv a good idea heading into Q4 results, says Baird
Baird analyst David Koning views Fiserv as a good idea heading into Q4 results. The analyst sees organic revenue growth set to accelerate and noted its current P/E is at a three year low on a post tax reform basis. Other catalysts include eventual bank spending improvement and high-margin debt processing growth. Koning reiterated his Outperform rating and raised his price target to $160 from $146 on Fiserv shares.
01/12/18
ARGS
01/12/18
NO CHANGE
ARGS
Fiserv price target raised to $148 from $140 at Argus
Argus analyst Jasper Hellweg maintained a Buy rating and raised his price target on Fiserv to $148 from $140. Hellweg expects Q4 to be the strongest of the year as the company completes implementations that were delayed in 2016, and sees "healthy upside" for Fiserv shares even without multiple expansion.
PRU Prudential
$111.17

0.18 (0.16%)

01/11/18
ATLE
01/11/18
UPGRADE
ATLE
Overweight
Prudential upgraded to Overweight from Neutral at Atlantic Equities
01/02/18
JPMS
01/02/18
UPGRADE
Target $87
JPMS
Overweight
Lincoln National upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Jimmy Bhullar upgraded Lincoln National (LNC) to Overweight and raised his price target for the shares to $87 from $74. The analyst expects "healthy" business trends, steady capital deployment and an attractive valuation to drive share outperformance. He calls Lincoln and Prudential (PRU) his top Life Insurance picks for 2018. Bhullar is negative on Brighthouse Financial (BHF) and Voya Financial (VOYA) heading into 2018.
01/02/18
DBAB
01/02/18
INITIATION
Target $124
DBAB
Hold
Prudential initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Joshua Shanker started Prudential with a Hold rating and $124 price target. The analyst believes return on equity improvement will be difficult in the near-term and finds the stock fairly valued.
01/19/18
SBSH
01/19/18
NO CHANGE
Target $63
SBSH
Buy
Citi removes Voya Financial, adds Prudential to Focus List
Citi analyst Suneet Kamath removed Voya Financial (VOYA) from his firm's Focus List saying the sale of its Annuity operation, a significant positive catalyst, is largely reflected in the valuation. The analyst keeps a Buy rating on the shares with a $63 price target. Kamath added Prudential (PRU) to the Focus List and keeps a Buy rating on the shares with a $130 price target. He believes the company could replace MetLife (MET) as the "default, large-cap life insurer in the space for investors to own." The analyst keeps a Sell rating on MetLife with a $48 price target.
GCAP GAIN Capital
$6.53

-0.2 (-2.97%)

ATHN athenahealth
$134.08

1.32 (0.99%)

02/05/18
RHCO
02/05/18
NO CHANGE
Target $180
RHCO
Buy
athenahealth price target raised to $180 from $156 at SunTrust
SunTrust analyst Sandy Draper raised his price target on athenahealth to $180, citing the company's Q4 earnings beat as well as his expectations of maintaining double-digit topline growth and operating margin expansion to 20% by 2019. Draper also points to improved investor visibility after the company "scrubbed" its bookings reporting to make them "higher quality" than in the prior period. The analyst keeps his Buy rating on athenahealth.
01/19/18
01/19/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Becton Dickinson (BDX) reinstated with a Buy at BofA/Merrill. 2. athenahealth (ATHN) initiated with an In Line at Evercore ISI. 3. Corbus Pharmaceuticals (CRBP) initiated with an Outperform at Raymond James. 4. Trade Desk (TTD) initiated with a Buy at Stifel. 5. Intellipharmaceutics (IPCI) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/18/18
EVER
01/18/18
INITIATION
Target $140
EVER
athenahealth initiated with an In Line at Evercore ISI
Evercore ISI initiated coverage of athenahealth with an In Line rating and $140 price target.
01/04/18
SBSH
01/04/18
INITIATION
Target $141
SBSH
Neutral
athenahealth initiated with a Neutral at Citi
Citi analyst Stephanie Davis started athenahealth with a Neutral rating and $141 price target. The analyst forecasts slowing growth given a "diminished greenfield opportunity" and "distraction potential as activist investor focus on margins."
GE General Electric
$15.25

-0.02 (-0.13%)

01/25/18
RBCM
01/25/18
NO CHANGE
Target $17
RBCM
Sector Perform
General Electric price target lowered to $17 from $20 at RBC Capital
RBC Capital analyst Deane Dray lowered his price target on General Electric to $17 and kept his Sector Perform rating after Q4 earnings, saying the celebration from the affirmed 2018 outlook was overshadowed by the disclosure of SEC investigations. The analyst notes the course of the investigation is uncertain, but it will keep many investors on the sidelines for now. Dray also says the turnaround in Power is likely to be "protracted" because of secular headwinds, adding that GE's expectations of 2017 ending with under 35GW in global awards is the company's lowest since 2002.
01/29/18
DBAB
01/29/18
NO CHANGE
Target $15
DBAB
Sell
SEC investigation 'significantly elevates' GE's risks, says Deutsche Bank
The SEC investigation disclosed on January 24 by General Electric "significantly elevates" the company's risks, Deutsche Bank analyst John Inch tells investors in a research note. GE is being investigated for both its revenue recognition and controls for long-term service agreements as well as the process that led to its insurance reserve increase and Q4 insurance reserve charge, Inch points out. The analyst believes the scope of the Enforcement Division's investigation "could readily broaden to other areas." General Electric was not obligated to disclose the investigation but likely did so having estimated that its potential impact might be significant, Inch writes, citing his understanding of the company's position. As such, the analyst thinks GE's verbal disclosure of the investigation "could portend an extensive review that might last for an extended period." Inch points out that long-term service agreements drove $2.2B of GE's net income in 2016, equating to 24c of earnings per share or 16% of its total adjust earnings for the year. The analyst has a Sell rating on GE with a $15 price target. The stock closed Friday down 5c to $16.13.
01/26/18
JPMS
01/26/18
NO CHANGE
Target $16
JPMS
Underweight
JPMorgan calls General Electric's annual guidance 'a stretch'
JPMorgan analyst C. Stephen Tusa keeps an Underweight rating and $16 price target on General Electric following an analysis of the company's Q4 results. "We are scratching our heads as to how the implied profit guide for 2018 is intact" with the $900M of miss in Q4, Tusa tells investors in a research note. He views GE's annual guidance as "a stretch." Further, the analyst does not know a how a value investor or ratings agency analyst "can have confidence in the ultimate value of the assets here." He continues to see a "levered industrial company with weak levels of FCF, with a side dish of levered finco, with a management team in the tough position, working to prevent a 'hard landing' in which bond investors start to worry about liquidity."
01/31/18
DBAB
01/31/18
NO CHANGE
Target $15
DBAB
Sell
GE likely to be dropped from Dow 30 index, says Deutsche Bank
General Electric (GE) is likely to be dropped from the Dow Jones Industrial Average after being in the index of 30 companies for over 110 years as an original member since 1896, Deutsche Bank analyst John Inch tells investors in a research note. The chances that GE could be removed from the Dow are increasing as the company continues to face "substantial challenges," the analyst writes. These include "earnings and cash pressure, tough global power generation markets, aggressive downsizing, shrinking its portfolio, management shake-up and SEC investigations," Inch argues. He sees "headline risk" as the most significant risk factor if GE were to be dropped from the Dow, "potentially amplified by GE's high mix of retail investors." Inch notes that the last major Dow shakeup occurred in September 2003, when American Airlines (AAL), Bank of America (BAC) and Hewlett Packard (HPQ) were removed and Goldman Sachs (GS), Nike (NKE) and Verizon (VZ) were added. Inch has a Sell rating on General Electric with a $15 price target. The shares closed yesterday down 33c to $15.95.
IRBT iRobot
$88.04

0.95 (1.09%)

12/04/17
12/04/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Buy at Monness Crespi. 2. iRobot (IRBT) initiated with a Neutral at Citi. 3. Asure Software (ASUR) initiated with a Buy at Craig-Hallum. 4. First Horizon (FHN) reinstated with an Equal Weight at Barclays. 5. CBTX (CBTX) was initiated with a Hold at Sandler O'Neill, an Overweight at Stephens, and a Market Perform at Keefe Bruyette. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/02/18
PIPR
01/02/18
NO CHANGE
PIPR
Neutral
iRobot checks suggest 'exceptionally strong quarter,' says Piper Jaffray
Piper Jaffray analyst Troy Jensen says his channel checks throughout the holiday season indicate the robotic vacuum market is experiencing "exceptionally strong demand" and that iRobot likely exceeded consensus expectations in Q4. Throughout the month of December, out-of-stock retailers increased to extremely high levels while pricing increased on Amazon's website, Jensen tells investors in a research note. He believes the data point to an "exceptionally strong quarter" for iRobot. The analyst, however, reiterates a Neutral rating on the shares with a $69 price target. He still has concerns that competition from Shark and others could eat into iRobot's share and margins, but admits this likely won't be an issue "anytime soon."
01/30/18
SIDC
01/30/18
DOWNGRADE
Target $98
SIDC
Neutral
iRobot downgraded to Neutral from Buy at Sidoti
Sidoti analyst Frank Camma downgraded iRobot to Neutral citing valuation as shares approach his $98 price target
01/30/18
01/30/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AbbVie (ABBV) downgraded to Underperform from Market Perform by analyst Alex Arfaei, who said the risk/reward has "meaningfully changed" after the rise in the stock price, adding that the new focus on fundamentals beyond the benefits of tax reform suggests "significant price erosion in immunology driven by interchangeable biosimilar anti-TNFs, and lower effectiveness of the 'Rebate Trap' to block access to cheap biosimilars". 2. iRobot (IRBT) downgraded to Neutral from Buy at Sidoti by analyst Frank Camma, who cited valuation as shares approach his $98 price target. 3. Horizon Global (HZN) downgraded to Market Perform from Outperform at BMO Capital by analyst Gerrick Johnson, who said that while he still sees "strong demand in key end markets," operation execution, rising input costs, and high debt levels are concerning. The analyst added that the company may have "lost the faith of investors" after a 30% drop in the stock price following the guidance cut. 4. Yum! Brands (YUM) downgraded to Neutral from Buy at Nomura Instinet by analyst Mark Kalinowshi, who cited valuation and concerns a possible 2018 slowdown in U.S. same-store-sales. 5. Alaska Air (ALK) downgraded to Underweight from Neutral at JPMorgan by analyst Jamie Baker, who noted that the airline is the only name where he had to cut his 2019 estimates. He also believes the company "remains in the United crosshairs in San Francisco." The analyst also downgraded Southwest (LUV) to Neutral from Overweight, and said he believes better relative value exists elsewhere in the Airlines sector. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
LCI Lannett
$20.40

0.6 (3.03%)

05/01/17
BMOC
05/01/17
INITIATION
Target $29
BMOC
Market Perform
Lannett initiated with a Market Perform at BMO Capital
BMO Capital analyst Gary Nachman started Lannett with a Market Perform rating and $29 price target. Macro headwinds are "very challenging for many generic companies," the analyst tells investors in a research note.
05/03/17
CHLM
05/03/17
NO CHANGE
Target $32
CHLM
Buy
Lannett price target lowered to $32 from $38 at Craig-Hallum
Craig-Hallum analyst Matt Hewitt lowered his price target for Lannett to $32 from $38 after the company noted that greater than anticipated price erosion in Q3 more than offset a meaningful year over year volume increase, culminating in a miss on revenues and adjusted EPS. The analyst reiterates a Buy rating on the shares, saying there are still several unique opportunities on the horizon for Lannett that give him reason for optimism.
08/24/17
CHLM
08/24/17
NO CHANGE
Target $32
CHLM
Buy
Craig-Hallum remains a buyer of Lannett
Craig-Hallum analyst Matt Hewitt says that while the sector continues to be under pressure with terms like "price erosion" and "increased competition" heard with more frequency to describe market dynamics, he continues to believe Lannett stock is undervalued. Despite a plethora of initiatives to drive growth and increasing cost synergies being realized from the Kremers Urban acquisition, the company trades at a "significant" discount to peers, he argues. Hewitt reiterates a Buy rating and $32 price target on the shares.
01/24/18
GSCO
01/24/18
INITIATION
Target $21
GSCO
Neutral
Lannett initiated with a Neutral at Goldman Sachs
Goldman analyst Dana Flanders initiated Lannett with a Neutral and $21 price target.
IPHI Inphi
$29.71

-2.38 (-7.42%)

01/19/18
01/19/18
DOWNGRADE
Target $36

Equal Weight
Inphi downgraded on longer than expected recovery at Morgan Stanley
As previously reported, Morgan Stanley analyst Joseph Moore downgraded Inphi to Equal Weight from Overweight, stating that management's indication that inventories continued to build last year is discouraging. With recovery pushed into the second half and the base business looking smaller than his prior expectations, Moore cut his price target on Inphi shares to $36 from $45.
01/22/18
JEFF
01/22/18
NO CHANGE
Target $40
JEFF
Buy
Inphi selloff Friday a buying opportunity, says Jefferies
Jefferies analyst Mark Lipacis recommends buying shares of Inphi following Friday's selloff. While the China inventory correction is worse than expected, the risk is now priced into the shares, Lipacis tells investors in a research note. The analyst likes Inphi's "differentiated leadership" in optical components and keeps a Buy rating on the shares. He cut his price target for the name to $40 from $50.
01/25/18
DADA
01/25/18
NO CHANGE
Target $34
DADA
Neutral
Inphi price target lowered to $34 from $40 at DA Davidson
DA Davidson analyst Mark Kelleher lowered his price target on Inphi to $34 and kept his Neutral rating ahead of Q4 results. Kelleher says that while the company offers an "industry leading" semiconductor solutions for data transport in the data center market, which is "one of the fastest growing areas of optical networking", much of the growth has already been priced into the stock. The analyst adds that the recent commentary from the management suggests that China demand remains weak.
01/19/18
BOFA
01/19/18
DOWNGRADE
Target $40
BOFA
Neutral
Inphi downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analsyt Vivek Arya downgraded Inphi to Neutral and lowered its price target to $40 from $46 following management commentary regarding continued uncertainty in China optical long haul and metro deployments, including excess inventory in its most profitable product of amplifiers. Arya believes Q1 could be down 10-15%, pressuring 2018 earnings and pushing out a recovery further into second half of 2018.
TTMI TTM Technologies
$15.48

-0.08 (-0.51%)

08/25/17
STFL
08/25/17
UPGRADE
STFL
Buy
TTM Technologies upgraded based on valuation at Stifel
As noted earlier, Stifel upgraded TTM Technologies to Buy from Hold. Analyst Matthew Sheerin upgraded the stock based on valuation. Target $17.50.
10/10/17
JPMS
10/10/17
DOWNGRADE
Target $62
JPMS
Neutral
Plexus downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Paul Coster downgraded Plexus (PLXS) to Neutral saying the shares are close to fair value after rallying 20% from a late-August low. The analyst recommends investors look at Flex (FLEX) and TTM Technologies (TTMI) as alternatives. He keeps a $62 price target for Plexus shares.
12/14/17
RHCO
12/14/17
INITIATION
Target $20
RHCO
Buy
TTM Technologies initiated with a Buy at SunTrust
SunTrust analyst William Stein initiated TTM Technologies with a Buy rating and a price target of $20. Stein says the company's run of acquisitions has made it the world's third largest manufacturer of printed circuit boards, creating a more stable business model. The analyst expects future acquisitions to further accelerate sales growth and boost margins.
01/24/18
JPMS
01/24/18
NO CHANGE
JPMS
JPMorgan names top long ideas for 2018 in Applied Tech Hardware
JPMorgan analyst Paul Coster believes Applied Tech Hardware stocks are positioned to post solid returns in 2018 owing to cyclical tailwinds and attractive relative valuations. The analyst favors electronic manufacturing solutions stocks in particular give their unit-driven exposure to Internet of Things device proliferation across verticals. His top long ideas for 2018 are Flex (FLEX), NCR Corp. (NCR), TTM Technologies (TTMI) and Zebra Technologies (ZBRA).
YELP Yelp
$44.94

0.66 (1.49%)

12/18/17
JPMS
12/18/17
NO CHANGE
Target $1375
JPMS
Overweight
JPMorgan calls Facebook, Priceline and Amazon top 2018 Internet picks
JPMorgan analyst Doug Anmuth raised his price target for Amazon.com (AMZN) to $1,375 from $1,220, for Priceline (PCLN) to $2,050 from $1,950 and for Yelp (YELP) to $55 from $52 in conjunction with his 2018 outlook for the Internet sector. The analyst this morning also upgraded Twitter (TWTR) to Overweight from Neutral and raised his price target for the shares to $27 from $20. Anmuth's best Internet ideas for 2018 are Facebook (FB), Priceline and Amazon for large-caps and Twitter and Yelp for smid-caps.
12/07/17
12/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Yelp (YELP) downgraded to Underweight from Neutral at Piper Jaffray with analyst Sam Kemp saying given the "messiness" of removing Eat24, investors missed that Yelp lowered organic fourth quarter guidance by 2%. 2. Toll Brothers (TOL) downgraded to Outperform from Strong Buy at Raymond James with analyst Buck Horne saying fiscal 2018 gross margins are more cautious than expected due to New York City headwinds ahead of an upcoming supply wave. 3. Priceline (PCLN) and Expedia (EXPE) were downgraded to Neutral from Buy at MKM Partners. 4. Ctrip.com (CTRP) downgraded to Neutral from Overweight at JPMorgan with analyst Alex Yao saying the introduced an opt-in option in early October by removing part of the default purchase setting of bundled products. 5. Allergan (AGN) downgraded to Hold from Buy at Argus analyst David Toung saying the company's Botox may face increasing competition from a botulinum toxin-based product being developed by Revance Therapeutics (RVNC) by 2020. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/05/18
SBSH
01/05/18
NO CHANGE
Target $1400
SBSH
Buy
Citi names Amazon top Internet pick for 2018, ups target to $1,400
Citi analyst Mark May remains bullish on the consumer Internet sector, especially over the near term. The analyst believes a "positive, tax reform fueled, business climate" should benefit the end-markets of the companies in the space. After outperformance in 2017, however, he recommends being more selective in 2018. Amazon.com (AMZN) moves up a spot to become his top-ranked pick for 2018. May sees the combination of greater than 30% sales growth, margin expansion and the current valuation as a "compelling mix." He raised his price target for Amazon shares to $1,400 from $1,250. May's most- to least-favored stocks under coverage, in order, are: Amazon, Expedia (EXPE), Facebook (FB), Priceline (PCLN), Alphabet (GOOGL), eBay (EBAY), Yelp (YELP), Twitter (TWTR), TripAdvisor (TRIP), Netflix (NFLX), GrubHub (GRUB), GoDaddy (GDDY), Despegar.com (DESP), trivago (TRVG), LendingClub (LC), Wayfair (W), Snap (SNAP), Zillow (ZG), Blue Apron (APRN) and Roku (ROKU), which he downgraded this morning to Sell.
01/08/18
JPMS
01/08/18
NO CHANGE
Target $230
JPMS
Overweight
JPMorgan calls Facebook best idea for 2018, ups target to $230
JPMorgan analyst Doug Anmuth calls Facebook (FB) his best idea for 2018 and raised his price target for the shares to $230 from $225. The social media giant closed Friday up $2.52 to $186.85. The analyst's favorite names for 2018 are Facebook, Priceline (PCLN) and Amazon (AMZN) among large-caps and Twitter (TWTR) and Yelp (YELP) among smid-caps. Facebook continues to show a "rare and impressive" combination of scale, growth and profitability, Anmuth tells investors in a research note. The analyst expects continued strong engagement and highlights the "rapid growth" at Instagram, which he believes could double over time and ultimately approach core Facebook platform scale. He keeps an Overweight rating on the shares.
TTWO Take-Two
$117.19

-1.08 (-0.91%)

02/02/18
OPCO
02/02/18
NO CHANGE
Target $135
OPCO
Outperform
Take-Two game delay does not impact estimates, says Oppenheimer
Oppenheimer analyst Andrew Uerkwitz says that while the Red Dead Redemption 2 delay is disappointing, he does not see it affecting his numbers or expectations for Take-Two Interactive. It is not out of the norm for Rockstar to delay games given its pursuit for the perfect title, Uerkwitz tells investors in a research note titled "Not 'On Shaky's Ground.'" The analyst is confident Red Dead Redemption 2 will remain the most anticipated game of the year. He keeps an Outperform rating on Take Two shares with a $135 price target.
02/01/18
PIPR
02/01/18
NO CHANGE
Target $125
PIPR
Overweight
Red Dead delay immaterial to Take-Two, says Piper Jaffray
Piper Jaffray analyst Michael Olson says the delay of Red Dead Redemption 2 until the fall will be immaterial to Take-Two Interactive. The company reiterated its fiscal 2019 guidance despite the delay, which is likely a sign of ongoing strength for GTA Online, Olson tells investors in a research note. He maintains an Overweight rating on Take-Two with a $125 price target.
02/01/18
BARD
02/01/18
NO CHANGE
BARD
Outperform
Additional Red Dead delay doesn't mean trouble for Take-Two, says Baird
Baird analyst Colin Sebastian noted that Take-Two Interactive has announced the launch of "Red Dead Redemption 2" has been pushed out further, but he believes the quality of content is more important than hitting "somewhat arbitrary commercial deadlines" and this latest delay is the right move. In addition to the prospects for better game play and user satisfaction, the title could benefit incrementally from a holiday-period release, said the analyst, who continues to estimate 18M units sold for RDR2 in FY19. Sebastian keeps an Outperform rating on Take-Two shares.
02/01/18
02/01/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Epizyme (EPZM) initiated with a Buy at Roth Capital. 2. Take-Two (TTWO) initiated with an Overweight at Morgan Stanley. 3. AMERI Holdings (AMRH) initiated with an Outperform at Northland. 4. Simply Good Foods (SMPl) initiated with a Buy at SunTrust. 5. Zynerba (ZYNE) assumed with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ORLY O'Reilly Automotive
$252.08

-2.82 (-1.11%)

12/19/17
SBSH
12/19/17
NO CHANGE
Target $290
SBSH
Buy
Citi names O'Reilly Automotive top 2018 pick in Hardlines
Citi analyst Kate McShane names O'Reilly Automotive her top Hardlines pick for 2018. The set up for auto parts companies looks more favorable headed into 2018 with easier compares and still positive industry dynamics, McShane tells investors in a research note. She views O'Reilly as the strongest auto parts retailer and upped her price target for the stock to $290 from $283. The analyst reiterates a Buy rating on the shares.
12/19/17
SBSH
12/19/17
UPGRADE
Target $117
SBSH
Buy
Walmart upgraded to Buy from Neutral at Citi
Citi analyst Kate McShane upgraded Walmart (WMT) to Buy and raised her price target for the shares to $117 from $106 saying the stock has "more room to run" in 2018. The retailing giant closed yesterday up 79c to $97.90. The company's "aggressive" omnichannel strategy will continue to drive "significant" sales growth, McShane tells investors in a research note. Further, the analyst believes Walmart's e-commerce operations are emerging as a "true challenger" to Amazon (AMZN). She sees both of these factors driving multiple expansion for Walmart shares. McShane also expects the company to announce a dividend increase. The analyst makes Walmart her number two pick in Broadlines and Hardlines for 2018, behind top pick O'Reilly Automotive (ORLY).
12/13/17
12/13/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Huntsman (HUN) reinstated with an Overweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas saying a strengthened balance sheet from asset sales, "healthy" Urethane Chemical business conditions and good free cash flow generation bring a favorable risk/reward. 2. Dentsply Sirona (XRAY) upgraded to Overweight from Neutral at JPMorgan with analyst Tycho Peterson saying he expects "meaningful improvement" to the company's organic growth in 2018, although he notes management's initial guidance will likely be conservative. 3. O'Reilly Automotive (ORLY) upgraded to Outperform from Sector Perform at RBC Capital with analyst Scot Ciccarelli saying that despite the 15% run-up in stock price last month, 2018 set-up remains favorable with building demand from mild weather, easing comps headwinds, and an attractive relative valuation. 4. Extra Space Storage (EXR) upgraded to Equal Weight at Morgan Stanley with analyst Richard Hill saying he expects relatively less deceleration of core growth in the fourth quarter and for its 2018 guidance to be in line with expectations. He raised his price target on Extra Space Storage to $83 from $70. 5. Taubman Centers (TCO) upgraded to Market Perform from Underperform at BMO Capital with analyst R. Jeremy Metz saying M&A activity, activist involvement, and speculation will keep shares supported in the near-term despite the challenging environment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/13/17
RBCM
12/13/17
UPGRADE
Target $282
RBCM
Outperform
O'Reilly Automotive upgraded to Outperform at RBC Capital on favorable 2018 view
As reported earlier, RBC Capital analyst Scot Ciccarelli upgraded O'Reilly Automotive to Outperform from Sector Perform and raised his price target to $282 from $218. Ciccarelli contends that despite the 15% run-up in stock price last month, 2018 set-up remains favorable with building demand from mild weather, easing comps headwinds, and an attractive relative valuation.
MRAM Everspin Technologies
$8.68

0.15 (1.76%)

11/14/17
CHLM
11/14/17
NO CHANGE
Target $14
CHLM
Buy
Everspin Technologies price target lowered to $14 from $19 at Craig-Hallum
Craig-Hallum analyst Richard Shannon lowered his price target for Everspin Technologies to $14 from $19 as shifting priorities create near-term pain. The analyst reiterates a Buy rating on the shares.
11/14/17
NEED
11/14/17
NO CHANGE
Target $17
NEED
Strong Buy
Everspin Technologies price target lowered to $17 from $24 at Needham
Needham analyst Rajvindra Gill lowered his price target on Everspin Technologies to $17 following Q3 results, saying the revenue miss was due in part to tool breaking. The analyst also notes the negative shift in focus to 256Mb as the primary ST-MRAM to bring to market versus dual 256Mb/1Gb, which could target the RAID storage market. Gill is keeping his Strong Buy rating, saying he continues to see "substantial value" in Everspin's technology, adding that the company is on the right path toward a broader market adoption.
08/14/17
ADAM
08/14/17
NO CHANGE
Target $18
ADAM
Buy
Everspin Technologies price target raised to $18 from $12 at Canaccord
Canaccord analyst Matthew Ramsay raised his price target on Everspin Technologies to $18 from $12 following solid Q2 results. The analyst cited its better than expected revenues and gross margins despite what the company called a transitional quarter. Ramsay believes once the company is scaled in terms of volume, density, and pricing, the company will be able to ramp into more mainstream enterprise DRAM applications. Ramsay reiterated his Buy rating on Everspin Technologies shares.
05/30/17
CHLM
05/30/17
NO CHANGE
Target $14
CHLM
Buy
Everspin Technologies executing well since IPO, says Craig-Hallum
Craig-Hallum analyst Richard Shannon said that after traveling with Everspin Technologies management he came away with an increased level of confidence in the company's execution. Everspin has "done everything it said it would do coming out of its IPO" last October, Shannon tells investors. The analyst, who views Everspin as uniquely positioned to prove out its higher density technology in new markets, keeps a Buy rating and $14 price target on the stock.
MNOV MediciNova
$9.73

-1.02 (-9.49%)

04/18/17
FBCO
04/18/17
INITIATION
FBCO
Outperform
MediciNova initiated with an Outperform at Credit Suisse
Credit Suisse analyst Dr Yen Tin Chen initiated MediciNova with an Outperform citing its pipeline of small molecules for neurological and fibrotic diseases with high unmet needs and expects the company to turn profitable from FY12/23.
ES Eversource
$56.89

-0.65 (-1.13%)

02/02/18
02/02/18
DOWNGRADE
Target $60

Neutral
Eversource downgraded to Neutral after Northern Pass denial at Janney Capital
As previously reported, Janney Capital analyst Michael Gaugler downgraded Eversource to Neutral from Buy after a New Hampshire committee voted against the Northern Pass Transmission project. The news was "extremely disappointing," especially given the lengths Eversource Energy went to gain approval, including additional costs to bury most of the line and significant concessions to various interested parties, said Gaugler. Given the doubt about the project's future, he expects the shares to trade at a discount to the peer group and lowered his fair value estimate on Eversource shares to $60.
02/02/18
FBCO
02/02/18
NO CHANGE
Target $59
FBCO
Underperform
NPT denial raises questions about Eversource growth, says Credit Suisse
Credit Suisse analyst Michael Weinstein noted that a New Hampshire committee unanimously voted to deny the application of Eversource and Hydro-Quebec's Northern Pass Transmission project. Eversource can appeal, but without approvals in New Hampshire, Massachusetts is likely to consider other bidders, said Weinstein, who sees the fight as likely heading to the courts. Weinstein keeps his $59 price target and Underperform rating on Eversource, adding that he sees a possibility for management to reduce its EPS growth projection to 4%-6%.
02/02/18
SBSH
02/02/18
DOWNGRADE
Target $54
SBSH
Sell
Eversource downgraded to Sell after Northern Pass rejection at Citi
Citi analyst Praful Mehta downgraded Eversource Energy to Sell from Neutral and cut his price target for the shares to $54 from $61. The analyst sees a "challenging growth profile" for Eversource after the New Hampshire Site Evaluation Committee voted to deny the Northern Pass project application. The analyst believes the legal challenge will be lengthy and thinks the company's growth will weaken to the 4%-5% range.
02/02/18
SBSH
02/02/18
DOWNGRADE
SBSH
Sell
Eversource downgraded to Sell from Neutral at Citi

TODAY'S FREE FLY STORIES

BHGE

Baker Hughes

$28.03

-0.01 (-0.04%)

04:55
02/24/18
02/24
04:55
02/24/18
04:55
Conference/Events
Baker Hughes management to meet with UBS »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

GE

General Electric

$14.49

-0.01 (-0.07%)

18:49
02/23/18
02/23
18:49
02/23/18
18:49
Periodicals
General Electric could face DOJ action over subprime mortgages, Reuters says »

General Electric may face…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEDU

Bright Scholar

$20.15

0.34 (1.72%)

18:30
02/23/18
02/23
18:30
02/23/18
18:30
Syndicate
Bright Scholar files to sell 10M American Depositary Shares »

Each ADS represents one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$132.02

2.11 (1.62%)

, CMD

Cantel Medical

$115.34

2.45 (2.17%)

18:03
02/23/18
02/23
18:03
02/23/18
18:03
Periodicals
J&J sterilization unit draws bids from Cantel Medical, Medtronic, Bloomberg says »

Cantel Medical (CMD) and…

JNJ

Johnson & Johnson

$132.02

2.11 (1.62%)

CMD

Cantel Medical

$115.34

2.45 (2.17%)

MDT

Medtronic

$80.39

-0.02 (-0.02%)

KKR

KKR

$21.96

0.18 (0.83%)

CG

Carlyle Group

$23.15

-0.1 (-0.43%)

MMM

3M

$237.02

1.02 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 08

    Mar

  • 14

    Mar

  • 23

    Mar

  • 23

    Apr

  • 30

    May

AET

Aetna

$175.55

0.49 (0.28%)

, CVS

CVS Health

$68.16

0.16 (0.24%)

18:00
02/23/18
02/23
18:00
02/23/18
18:00
Hot Stocks
Aetna: CVS deal part of long-term solution toward value-based system »

According to prepared…

AET

Aetna

$175.55

0.49 (0.28%)

CVS

CVS Health

$68.16

0.16 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

  • 30

    May

MYND

MYnd Analytics

$2.60

0.0301 (1.17%)

17:56
02/23/18
02/23
17:56
02/23/18
17:56
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYND

MYnd Analytics

$2.60

0.0301 (1.17%)

17:55
02/23/18
02/23
17:55
02/23/18
17:55
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRV

ContraVir Pharmaceuticals

$0.27

0.0027 (1.02%)

17:43
02/23/18
02/23
17:43
02/23/18
17:43
Hot Stocks
Gabriele Cerrone reports 7.0% stake in ContraVir Pharma, may seek board changes »

The shares of common…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$40.98

0.09 (0.22%)

17:41
02/23/18
02/23
17:41
02/23/18
17:41
Periodicals
VW settles U.S. diesel suit just before trial, Reuters reports »

Volkswagen's U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAC

IAC

$153.99

3.2 (2.12%)

17:40
02/23/18
02/23
17:40
02/23/18
17:40
Hot Stocks
Breaking Hot Stocks news story on IAC »

Barry Diller reports 8.3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SPG

Simon Property

$156.66

2.63 (1.71%)

17:37
02/23/18
02/23
17:37
02/23/18
17:37
Syndicate
Breaking Syndicate news story on Simon Property »

Simon Property files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$28.64

0.99 (3.58%)

17:35
02/23/18
02/23
17:35
02/23/18
17:35
Hot Stocks
Fabrinet director Frank Levinson buys 10,000 shares of company stock »

Frank Levinson, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 12

    Mar

  • 29

    Mar

CASI

Casi Pharmaceuticals

$3.85

0.1 (2.67%)

17:33
02/23/18
02/23
17:33
02/23/18
17:33
Syndicate
Breaking Syndicate news story on Casi Pharmaceuticals »

Casi Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXCM

Dexcom

$56.36

-0.04 (-0.07%)

, TNDM

TNDM

17:31
02/23/18
02/23
17:31
02/23/18
17:31
Hot Stocks
Breaking Hot Stocks news story on Dexcom, TNDM »

DexCom reports 5.6%…

DXCM

Dexcom

$56.36

-0.04 (-0.07%)

TNDM

TNDM

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 01

    Mar

  • 04

    Mar

IDXX

Idexx Laboratories

$187.61

3.75 (2.04%)

17:24
02/23/18
02/23
17:24
02/23/18
17:24
Hot Stocks
Idexx Laboratories director sells 4,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 04

    Mar

CYDY

CytoDyn

$0.72

0.02 (2.86%)

17:23
02/23/18
02/23
17:23
02/23/18
17:23
Syndicate
Breaking Syndicate news story on CytoDyn »

CytoDyn files $200M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRUS

Merus

17:23
02/23/18
02/23
17:23
02/23/18
17:23
Hot Stocks
Breaking Hot Stocks news story on Merus »

Biotechnology Value Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

MSG

Madison Square Garden

$231.97

2.41 (1.05%)

17:19
02/23/18
02/23
17:19
02/23/18
17:19
Hot Stocks
Silver Lake reports 4.9% stake in Madison Square Garden, may seek talks »

Silver Lake are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKL

Markel

$1,121.90

14.9 (1.35%)

17:12
02/23/18
02/23
17:12
02/23/18
17:12
Syndicate
Breaking Syndicate news story on Markel »

Markel files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEDU

Bright Scholar

$20.15

0.34 (1.72%)

17:08
02/23/18
02/23
17:08
02/23/18
17:08
Syndicate
Bright Scholar files to sell 10M American Depositary Shares »

Each ADS represents one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$162.09

2.69 (1.69%)

, MYL

Mylan

$41.45

0.17 (0.41%)

17:04
02/23/18
02/23
17:04
02/23/18
17:04
Periodicals
PTAB denies Allergan's bid to dismiss restasis patent challenge, Bloomberg says »

Allergan's (AGN)…

AGN

Allergan

$162.09

2.69 (1.69%)

MYL

Mylan

$41.45

0.17 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 19

    Mar

  • 25

    Mar

  • 23

    Apr

  • 13

    Nov

SCHW

Charles Schwab

$52.74

0.71 (1.36%)

17:03
02/23/18
02/23
17:03
02/23/18
17:03
Hot Stocks
Charles Schwab appoints Joseph Martinetto as COO of the firm »

On February 22, the board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KHC

Kraft Heinz

$69.02

1.38 (2.04%)

, BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

17:02
02/23/18
02/23
17:02
02/23/18
17:02
Hot Stocks
Kraft Heinz announces retirement of Warren Buffett from Board of Directors »

The Kraft Heinz Company…

KHC

Kraft Heinz

$69.02

1.38 (2.04%)

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

BUD

AB InBev

$107.25

1.91 (1.81%)

QSR

Restaurant Brands

$59.46

1.02 (1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 07

    Mar

  • 18

    Mar

SWX

Southwest Gas

$69.17

1.65 (2.44%)

17:02
02/23/18
02/23
17:02
02/23/18
17:02
Hot Stocks
Southwest Gas increases quarterly common stock dividend »

The board for Southwest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

MS

Morgan Stanley

$56.07

1.21 (2.21%)

, AAOI

Applied Optoelectronics

$28.02

0.51 (1.85%)

16:56
02/23/18
02/23
16:56
02/23/18
16:56
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley, Applied Optoelectronics »

Morgan Stanley reports…

MS

Morgan Stanley

$56.07

1.21 (2.21%)

AAOI

Applied Optoelectronics

$28.02

0.51 (1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 25

    Feb

  • 12

    Mar

  • 13

    Mar

  • 29

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.